Current Report Filing (8-k)
December 23 2022 - 04:20PM
Edgar (US Regulatory)
0001174940 false 0001174940 2022-12-22
2022-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report:
December 22, 2022
(Date
of earliest event reported)
Oragenics, Inc.
(Exact
name of registrant as specified in its charter)
|
FL |
|
001-32188 |
|
59-3410522 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
|
4902 Eisenhower Boulevard,
Suite 125
Tampa,
FL
|
|
33634 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock |
|
OGEN |
|
NYSE American |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. OTHER EVENTS.
On
December 23, 2022, Oragenics, Inc. (the “Company”) issued a press
release announcing that on December 22, 2022 the Board of Directors
approved a 1-for-60 reverse stock split of the Company’s
outstanding and authorized shares of common stock, pursuant to
Section 607.10025 of the Florida Business Corporation Act (the
“FBCA”), and the filing of Articles of Amendment to the Company’s
Amended and Restated Articles of Incorporation Section 607.10025 of
the FBCA. The effective date of the reverse stock split is
anticipated to be January 20, 2023 and the Company’s common stock
to begin trading on a split-adjusted basis when the market opens on
January 23, 2023 under the existing trading symbol
“OGEN”.
A
copy of the press release announcing these events is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
Item
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized on this 23rd day
of December, 2022.
|
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
|
|
BY: |
/s/
Kimberly Murphy |
|
|
|
Kimberly
Murphy
President
and Chief Executive Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to May 2023
Oragenics (AMEX:OGEN)
Historical Stock Chart
From May 2022 to May 2023
